Related Experiment Video

Updated: May 20, 2026

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

[Correction of secondary hyperlipidemia in children with diabetes]

N V Gonchar, I Iu Mel'nikova, T V Il'ina

    Eksperimental'Naia I Klinicheskaia Gastroenterologiia = Experimental & Clinical Gastroenterology
    |July 20, 2012
    PubMed

    Insights

    This study found that Bifiform Baby probiotic effectively reduced triglycerides, cholesterol, and betalipoproteins in children with insulin-dependent diabetes mellitus. It offers an advantage in treating secondary hyperlipidemia by addressing key lipid metabolism issues.

    Area of Science:

    • Pediatrics
    • Endocrinology
    • Gastroenterology

    Background:

    • Children with insulin-dependent diabetes mellitus (IDDM) often experience secondary hyperlipidemia during decompensation.
    • Hypertriglyceridemia is a primary metabolic disturbance in this condition.

    Purpose of the Study:

    • To evaluate the efficacy of Bifiform Baby probiotic in correcting secondary hyperlipidemia in children with IDDM.
    • To compare the effects of probiotic supplementation versus standard therapy on lipid profiles.

    Main Methods:

    • A study involving 25 children with IDDM in decompensation.
    • The basic group (n=11) received insulin, a lipotrophic agent, and Bifiform Baby.
    • The comparison group (n=14) received insulin and a lipotrophic agent.

    Main Results:

    • The basic group showed a significant decrease in triglycerides (TG), total cholesterol (TH), and betalipoproteins (BLP).
    • The comparison group demonstrated a decrease in TH and BLP, but not TG.
    • Bifiform Baby effectively reduced hypertriglyceridemia, a key lipid metabolism issue.

    Conclusions:

    • Bifiform Baby is advantageous in treating secondary hyperlipidemia in children with diabetic ketoacidosis.
    • Probiotic supplementation aids in normalizing lipid metabolism, particularly hypertriglyceridemia, in pediatric IDDM patients.

    Related Concept Videos

    Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

    Lipid-Lowering Drugs: Statins and Miscellaneous Agents

    Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
    Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

    Pharmacokinetics in Pediatric Patients: Drug Metabolism

    In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
    Hyperglycemia01:29

    Hyperglycemia

    Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...
    Type II Diabetes II: Pathophysiology01:24

    Type II Diabetes II: Pathophysiology

    PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
    Type I Diabetes II: Pathophysiology01:26

    Type I Diabetes II: Pathophysiology

    Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
    Hypoglycemia01:26

    Hypoglycemia

    Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...